Arovella Therapeutics Ltd (ASX:ALA)'s Michael Baker speaks to a newly acquired, exclusive global licence for the patent rights to a monoclonal antibody, which has been developed as a cancer treatment. Arovella secured the antibody licence from MD Anderson — the largest cancer research and treatment centre in the US. Looking ahead, Baker says Arovella will team the tech with its invariant Natural Killer T (iNKT) cell therapy platform to explore its therapeutic potential.
Arovella Therapeutics licenses the rights to monoclonal antibody for cancer treatment
